<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505218</url>
  </required_header>
  <id_info>
    <org_study_id>PER 2010/232-31</org_study_id>
    <nct_id>NCT01505218</nct_id>
  </id_info>
  <brief_title>Propofol Patient-controlled Sedation for Endoscopic Retrograde Cholangiopancreatography</brief_title>
  <acronym>PER-projekt</acronym>
  <official_title>Patient-controlled Propofol Sedation for Endoscopic Retrograde Cholangiopancreatography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lena Nilsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol sedation with opioids is used for endoscopic retrograde cholangiopancreatography
      (ERCP). Combination of sedatives and opioids is associated with increased
      morbidity/mortality. Delivery of only propofol using a patient-controlled delivery system
      (patient-controlled sedation, PCS) could be an alternative for this purpose. Comparative
      studies with PCS for ERCP are few. Therefore, the main objective of this randomized
      controlled trial was to compare propofol PCS to sedation managed by nurse anaesthetists
      during ERCP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatability</measure>
    <time_frame>one day (per-procedural)</time_frame>
    <description>Registration of number of failures (where procedure is interrupted as a result of inadequate sedation). Comparison data between propofol PCS and nurse anaesthetists sedation using propofol and control group (midazolam).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>one and a half year</time_frame>
    <description>Vital signs and interventions of nurse anaesthetists. Data on heart rate, blood pressure, peripheral oxygen saturatuion, respiratory rate, delivery of oxygen, airway obstruction assessment, airway manipulation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Endoscopic Retrograde Cholangiopancreatography</condition>
  <arm_group>
    <arm_group_label>Propofol sedation by nurse anaesthetist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient-controlled propofol sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.
Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam sedation by the ERCP-team</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol sedation by nurse anaesthestist</intervention_name>
    <description>Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.
Propofol sedation by nurse anaesthetists:</description>
    <arm_group_label>Propofol sedation by nurse anaesthetist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patient-controlled propofol sedation</intervention_name>
    <description>Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.
Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness.</description>
    <arm_group_label>Patient-controlled propofol sedation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Need for ERCP

          -  Able to speak and read swedish

        Exclusion Criteria:

          -  Allergy to propofol

          -  Severe cardiopulmonary disease (ASA IV)

          -  Confusion or dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Folke Sjöberg, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Anaesthesia and Intensive Care, Linköping University Hospital, 581 85 Linköping, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Lena Nilsson</investigator_full_name>
    <investigator_title>MD, PhP, senior consultant</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>propofol</keyword>
  <keyword>patient-controlled</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

